The clinical significance and mechanism of microRNA-22-3p targeting TP53 in lung adenocarcinoma

Article type: Research Article

Authors: Lin, Rui^a | Li, Guo-Sheng^b | Gan, Xiang-Yu^a | Peng, Jun-Xi^a | Feng, Yue^a | Wang, Li-Ting^a | Zhang, Chu-Yue^a | Huang, Kun-Ying^a | Huang, Shi-Hai^a | Yang, Lin^a | Kong, Jin-Liang^c | Zhou, Hua-Fu^b | Chen, Gang^a | Huang, Wan-Ying^{a; *}

Affiliations: [a] Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China | [b] Department of Cardio-Thoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China | [c] Ward of Pulmonary and Critical Care Medicine, Department of Respiratory Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

Correspondence: [*] Corresponding author: Wan-Ying Huang, Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, No. 6. Shuangyong Rd., Nanning, Guangxi 530021, China. E-mail: huangwanying_gxmu@163.com.

Abstract: BACKGROUND: At present, studies on MircoRNA-22-3p (miR-22-3p) in lung adenocarcinoma use a single method, lack multi-center validation and multi-method validation, and there is no big data concept to predict and validate target genes. OBJECTIVE: To investigate the expression, potential targets and clinicopathological significance of miR-22-3p in lung adenocarcinoma (LUAD) tissues. METHODS: LUAD formalin-fixed paraffin-embedded (FFPE) tumors and adjacent normal lung tissues were collected for real-time quantitative polymerase chain reaction (RT-qPCR). Collect miR-22-3p in LUAD and non-cancer lung tissue from high-throughput datasets, standardized mean difference (SMD) and area under the curve (AUC) of the comprehensive receiver operating curve (summary receiver operating characteristic cure, sROC curve) were calculated. Cell function experiments on A549 cells transfected with LV-hsa-miR-22-3p. Target genes were predicted by the miRwalk2.0 website and the resulting target genes were subjected to Gene Ontology (GO) pathway enrichment analysis and constructed to protein-protein interaction network. Finally, the protein expression level of the key gene TP53 was validated by searching The Human Protein Atlas (THPA) database to incorporate TP53 immunohistochemical results in LUAD. RESULTS: RT-qPCR result from 41 pairs of LUAD and adjacent lung tissues showed that miR-22-3p was downregulated in LUAD (AUC = 0.6597, p= 0.0128). Globally, a total of 838 LUADs and 494 non-cancerous lung tissues were included, and were finally combined into 14 platforms. Compared with noncancerous tissue, miR-22-3p expression level was significantly reduced in LUAD tissue (SMD =-0.32, AUC = 0.72l); cell function experiments showed that miR-22-3p has inhibitory effects on cell proliferation, migration and invasion, and has promotion effect on apoptosis. Moreover, target genes prediction, GO pathway enrichment analysis and PPI network exhibited TP53 as a key gene of target gene of miR-22-3p; at last, a total of 114 high-throughput datasets were included, including 3897 LUADs and 2993 non-cancerous lung tissues, and were finally combined into 37 platforms. Compared with noncancerous tissue, TP53 expression level was significantly increased in LUAD (SMD = 0.39, p< 0.01) and it was verified by the protein expression data from THPA. CONCLUSION: Overexpression of miR-22-3p may inhibit LUAD cell proliferation, migration and invasion through TP53, and promote cell apoptosis.

Keywords: miR-22-3p, lung adenocarcinoma, target gene, TP53

DOI: 10.3233/THC-220494

Journal: Technology and Health Care, vol. 31, no. 5, pp. 1691-1707, 2023